单位：[1]China Japan Friendship Hosp, Beijing, Peoples R China[2]Fourth Mil Med Univ, Xijing Hosp, Xian, Shaanxi, Peoples R China[3]China Med Univ, Hosp 1, Shenyang, Liaoning, Peoples R China[4]Anhui Med Univ, Affiliated Hosp 1, Hefei, Anhui, Peoples R China[5]Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China中山大学附属第一医院[6]Shanxi Med Univ, Hosp 2, Taiyuan, Shanxi, Peoples R China[7]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China
出处：
ISSN：
基金：
Jiangsu Hansoh Pharmaceutical Group Co., Ltd., China
第一作者单位：[1]China Japan Friendship Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Yang W.,Ji Q.,Shan Z.,et al.Efficacy and safety of PEX168, a novel once-weekly GLP-1 RA, for monotherapy in patients with type 2 diabetes: a phase 3a study[J].DIABETOLOGIA.2019,62:S367-S367.
APA：
Yang, W.,Ji, Q.,Shan, Z.,Zhang, Q.,Li, Y....&Qin, G..(2019).Efficacy and safety of PEX168, a novel once-weekly GLP-1 RA, for monotherapy in patients with type 2 diabetes: a phase 3a study.DIABETOLOGIA,62,
MLA：
Yang, W.,et al."Efficacy and safety of PEX168, a novel once-weekly GLP-1 RA, for monotherapy in patients with type 2 diabetes: a phase 3a study".DIABETOLOGIA 62.(2019):S367-S367
医学